Harmony Biosciences (HRMY) Q1 2025 earnings summary

Executive summary

• Achieved Q1 2025 net product revenue of $184.7 million, up 20% year-over-year, with continued profitability and cash and investments totaling $610.2 million as of March 31, 2025.

• Net income rose to $45.6 million, with non-GAAP adjusted net income of $60.4 million ($1.03 per diluted share), marking four consecutive years of profitability.

• Maintains a robust late-stage pipeline with up to eight assets across 13 development programs, including four ongoing Phase 3 trials and multiple anticipated catalysts in 2025.

• Expanded pipeline through acquisitions and licensing, including Epygenix Therapeutics and an orexin-2 receptor agonist.

• WAKIX remains the sole commercial product, with ongoing efforts to expand indications and obtain pediatric exclusivity.

Financial highlights

• Q1 2025 net product revenue: $184.7 million, up 20% from $154.6 million in Q1 2024.

• Non-GAAP adjusted net income: $60.4 million ($1.03/diluted share), up from $50.7 million ($0.88/share) year-over-year.

• GAAP net income: $45.6 million ($0.78/diluted share), up from $38.3 million ($0.67/diluted share) in Q1 2024.

• Operating expenses rose to $96.5 million, up 29% year-over-year, with R&D up 56%, S&M up 13%, and G&A up 22%.

• Gross profit increased to $152.7 million from $127.1 million year-over-year.

Outlook and guidance

• Reiterates 2025 net revenue guidance of $820 million–$860 million, with confidence in achieving $1+ billion in narcolepsy alone.

• Multiple late-stage pipeline catalysts expected in 2025, including Phase 3 trial initiations and data readouts.

• Management expects existing liquidity to fund operations and investing activities for at least the next 12 months.